GS Effex® Cell Line for Enhanced Antibody Effector Function

All you love from GS Xceed®, now fucose-free.

GS Effex®, derived from Lonza’s leading GS Xceed® cell line, produces molecules that are 100% free of fucose and demonstrate increased potency, without compromising on the titers, growth, stability and product quality that GS Xceed® is known for.

>35 Years' Experience

We have extensive experience in developing and delivering with market leading protein expression platforms.

Scalable and Regulatory-compliant Processes

We can help you develop robust, efficient, scalable and regulatory-compliant processes to equip you for ultimate commercial success.

>75 Molecules

In clinic manufactured with our expression platforms.

Produce more potent and effective cytotoxic therapeutic antibodies

The interaction of the IgG antibody Fc region with Fc receptors on immune effector cells engages antibody-dependent cellular cytotoxicity (ADCC) to induce target cell death. Removal of fucose residues on the Fc region has been shown to enhance ADCC, increasing the potency of antibody immunotherapies.

GS Effex^®, derived from Lonza’s leading GS Xceed^® cell line, has been engineered to lack the enzyme responsible for the addition of fucose, α1,6-fucosyltransferase. This industrially relevant cell line produces antibodies free of fucose, yet retains all of the desirable performance attributes of GS Xceed^®.

Download the flyer

Fucosylated antibody

Afucosylated antibody

Access to industry-leading technologies

GS Effex^® is available to license as part of Lonza’s GS Gene Expression System^®.A plug and play addition to the GS^®toolbox, it is fully compatible with GS^® workflows and processes.